THE β-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the
non-syncytium-inducing (NSI) phenotype with CD4 + T-cells 1–5 . The primary binding site …

HIV-1 entry into CD4 + cells requires the sequential interactions of the viral envelope
glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4. A …

We have isolated and characterized human monoclonal antibody 2G12 to the gp120 surface
glycoprotein of human immunodeficiency virus type 1 (HIV-1). This antibody potently and …

To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …

We have tested three human monoclonal antibodies (MAbs) IgG1b12, 2G12, and 2F5) to the
envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1), and a tetrameric …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), is a recently emerged respiratory coronavirus that has infected >…

Vaccination against human immunodeficiency virus type 1 (HIV-1) requires an immunogen
which will elicit a protective immunity against viruses that show a high degree of genetic …

HIV-1 enters its target cells by fusion at the plasma membrane. The primary cellular receptor
for HIV is CD4, but this molecule is insufficient to permit viral fusion. During 1996, the …

We have established a hybridoma clone, designated 2F5, secreting a neutralizing human
monoclonal antibody (MAb) specific for gp41 of human immunodeficiency virus type 1 (HIV-1). …

Rapid rebound of plasma viremia in patients after interruption of long-term combination
antiretroviral therapy (cART) suggests persistence of low-level replicating cells or rapid …